Siraj Ali
Overview
Explore the profile of Siraj Ali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
2022
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Mehnert J, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, et al.
J Clin Invest
. 2016 May;
126(6):2334-40.
PMID: 27159395
Antibodies that target the immune checkpoint receptor programmed cell death protein 1 (PD-1) have resulted in prolonged and beneficial responses toward a variety of human cancers. However, anti-PD-1 therapy in...
32.
Suh J, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, et al.
Oncologist
. 2016 May;
21(6):684-91.
PMID: 27151654
Background: The National Comprehensive Cancer Network (NCCN) guidelines for patients with metastatic non-small cell lung cancer (NSCLC) recommend testing for EGFR, BRAF, ERBB2, and MET mutations; ALK, ROS1, and RET...
33.
Liu X, Rice S, Jamis-Dow C, Abendroth C, Ali S, Almokadem S, et al.
Thorax
. 2016 Feb;
71(4):383-5.
PMID: 26839360
No abstract available.
34.
Campregher P, Pereira W, Lisboa B, Puga R, Helman R, Miyagi M, et al.
Mol Cancer
. 2015 Nov;
14:197.
PMID: 26584717
The ETV6 gene encodes an ETS family transcription factor that is involved in a myriad of chromosomal rearrangements found in hematological malignancies and other neoplasms. A recurrent ETV6 translocation, previously...
35.
Chumsri S, Weidler J, Ali S, Balasubramanian S, Wallweber G, DeFazio-Eli L, et al.
J Natl Compr Canc Netw
. 2015 Sep;
13(9):1066-70.
PMID: 26358791
In the current genomic era, increasing evidence demonstrates that approximately 2% of HER2-negative breast cancers, by current standard testings, harbor activating mutations of ERBB2. However, whether patients with HER2-negative breast...
36.
Ross J, Badve S, Wang K, Sheehan C, Boguniewicz A, Otto G, et al.
Arch Pathol Lab Med
. 2015 May;
139(5):642-9.
PMID: 25927147
Context: Metastatic metaplastic breast carcinoma (MPBC) is an uncommon, but aggressive, tumor resistant to conventional chemotherapy. Objective: To learn whether next-generation sequencing could identify potential targets of therapy for patients...
37.
Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, et al.
Cancer Discov
. 2014 Aug;
4(9):1022-35.
PMID: 25082755
Unlabelled: Despite the unprecedented clinical activity of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib in mantle cell lymphoma (MCL), acquired resistance is common. By longitudinal integrative whole-exome and whole-transcriptome sequencing...
38.
Ross J, Wang K, Gay L, Al-Rohil R, Rand J, Jones D, et al.
Oncologist
. 2014 Feb;
19(3):235-42.
PMID: 24563076
Background: Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer that is rarely curable by surgery and is rapidly increasing in incidence. Relapsed ICC has a poor prognosis, and...
39.
Ross J, Wang K, Gay L, Al-Rohil R, Nazeer T, Sheehan C, et al.
Clin Cancer Res
. 2013 Nov;
20(1):68-75.
PMID: 24192927
Purpose: Micropapillary urothelial carcinoma (MPUC) is a rare and aggressive form of bladder cancer. We conducted genomic analyses [next-generation sequencing (NGS)] of MPUC and non-micropapillary urothelial bladder carcinomas (non-MPUC) to...
40.
Ross J, Wang K, Al-Rohil R, Nazeer T, Sheehan C, Otto G, et al.
Mod Pathol
. 2013 Jul;
27(2):271-80.
PMID: 23887298
Although urothelial carcinoma (UC) of the urinary bladder generally portends a favorable prognosis, metastatic tumors often follow an aggressive clinical course. DNA was extracted from 40 μm of formalin-fixed, paraffin-embedded...